Shared Tumor Antigen Peptide Vaccines

Another active-specific immunotherapy with potential antitumor effect in CML relies on the use of intracellular proteins other than p210. In fact a number of self proteins are aberrantly overexpressed in CML and other tumor cells while being expressed at low levels in normal lineages and thus may function as targets for directed immunotherapy of residual disease. As in the case of p210, despite the intracellular location of these proteins, short peptides produced by their cellular processing...

Clinical Development Of Dasatinib In Chronic Myeloid Leukemia

Dasatinib was first investigated in a phase I dose-escalating study involving patients with CML in all phases who had failed or developed intolerance to imati-nib therapy (Table 1). Initially, dasatinib was administered only to patients with CP on a once-daily schedule for five consecutive days, followed by two days without treatment every week, and later a twice-daily administration was also investigated as well as a continuous daily administration. After clinical activity was observed in CP,...

References

Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005 11(9) 3425-3432. 2. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004 104(7) 2204-2205. 3. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to...

True Chronic Myeloid Leukemia Specific Antigen Vaccines

Tumor Associated Antigen Definition

The BCR-ABL-derived p210 protein and particularly the alternative b3a2 or b2a2 peptide epitope at its fusion point is the most obvious CML-specific target, and thus was first explored for a vaccine strategy. p210 is exclusive to the CML clone, and the sequences of amino acids contained in the b3a2 and b2a2 junctional regions represent unique tumor-specific determinants, which can be exploited for an immunological attack against the tumor cell 11 . Recent data support the hypothesis that...